AI-generated summary
The authors reviewed published studies on physical therapies for vulvovaginal atrophy, including vaginal laser, radiofrequency, photobiomodulation, and injections. They report few randomized trials for vaginal laser, no clear superiority of fractional CO2 laser over local estrogen, and reported risks such as stenosis and chronic pain. They conclude that vaginal lasers are not first-line treatment, while evidence for other physical therapies is weak.
- Who or what was studied
- Postmenopausal women with vulvovaginal atrophy or genitourinary syndrome of menopause
- Limits stated in the abstract
- The abstract notes few randomized controlled trials, short follow-up for vaginal laser, case series reporting risks, and weak literature on other physical treatments in the genital area.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Laser, Photobiomodulation therapy, Photobiomodulation, Systematic review, Contraindication, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.